No KRAS mutations found in gastrointestinal stromal tumors (GISTs): Molecular genetic study of 514 cases

Modern Pathology

Volumn 26, Issue 11, 2013, Pages 1488-1491

  Lasota, Jerzy ^a   Xi, Liqiang ^a   Coates, Tiffany ^a   Dennis, Rashonda ^a   Evbuomwan, Moses O ^a   Wang, Zeng Feng ^a   Raffeld, Mark ^a   Miettinen, Markku ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

GIST; KIT mutations; KRAS mutations; PDGFRA mutations; pyrosequencing; Sanger sequencing

Indexed keywords

K RAS PROTEIN;

ARTICLE; GASTROINTESTINAL STROMAL TUMOR; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PYROSEQUENCING;

DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; GASTROINTESTINAL STROMAL TUMORS; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; INTESTINAL NEOPLASMS; MUTATION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RISK FACTORS; STOMACH NEOPLASMS;

EID: 84887111618     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.89     Document Type: Article

References (22)

1. Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol 2011;104: 865-873.
2. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360-5367.
3. Miranda C, Nucifora M, Molinari F, et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res 2012;18:1769-1776.
4. Demetri GD. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. Semin Oncol 2011;38(Suppl 1):S10-S19.
5. Li J, Wang L, Mamon H, et al. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med 2008;14:579-584. (Pubitemid 351655208)
6. Miettinen M, Wang ZF, Sarlomo-Rikala M, et al. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol 2011;35:1712-1721.
7. Parada LF, Tabin CJ, Shih C, et al. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 1982;297:474-478. (Pubitemid 12007526)
8. Der CJ, Krontiris TG, Cooper GM. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci USA 1982;79:3637-3640. (Pubitemid 12014525)
9. Rodriguez-Viciana P, Tetsu O, Oda K, et al. Cancer targets in the ras pathway. Cold Spring Harbor Symposia and Qantitative Biology Vol. 70 (Cold Sprin Harbor Laboratory Press 2005.
10. Jebar AH, Hurst CD, Tomlinson DC, et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005;24:5218-5225. (Pubitemid 41192438)
11. Benesova L, Minarik M, Jancarikova D, et al. Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors. Anticancer Res 2010;30:1667-1671.
12. Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer 2011;2:344-358.
13. Yoo J, Robinson RA, Lee JY. H-ras and K-ras gene mutations in primary human soft tissue sarcoma: concomitant mutations of the ras genes. Mod Pathol 1999;12:775-780. (Pubitemid 29383880)
14. Hill MA, Ch Gong, Casey TJ, et al. Detection of K-ras mutations in resected primary leiomyosarcoma. Cancer Epidemiol Biomarkers Prev 1997;6:1095-1100. (Pubitemid 28007423)
15. Agaimy A, Terracciano LM, Dirnhofer S, et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol 2009;62:613-616.
16. Martinho O, Gouveia A, Viana-Pereira M, et al. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs. Histopathology 2009;55:53-62.
17. Daniels M, Lurkin I, Pauli R, et al. Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett 2011;312: 43-54.
18. Origone P, Gargiulo S, Mastracci L, et al. Molecular characterization of an Italian series of sporadic GISTs. Gastric Cancer; advance online publication, 5 January 2013 [e-pub ahead of print].
19. Otsuka K, Satoyoshi R, Nanjo H, et al. Acquired/intratumoral mutation of KRAS during metastatic progression of colorectal carcinogenesis. Oncology Letters 2012;3:649-653.
20. Falchook GS, Trent JC, Heinrich MC, et al. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget 2013; 4:310-315.
21. Tsiatis AC, Norris-Kirby A, Rich RG, et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn 2010;12:425-432.
22. Begley CG, Ellis LM. Drug development: raise standards for preclinical cancer research. Nature 2012; 483:531-533.